XNAS
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.37 | -0.39 | -5.41% | $0 | ❌ Miss | +0.24% | +5.25% | — |
| 2026-05-12 | Q1 2026 | -0.56 | -0.62 | -10.71% | $0 | ❌ Miss | -0.26% | +4.11% | -7.49% |
| 2026-03-19 |
| Q4 2025 |
| -0.12 |
| 2.90 |
| +2516.67% |
| $0 |
| ✅ Beat |
| -0.99% |
| +33.49% |
| +38.54% |
Showing last 3 quarters.